BioCentury
ARTICLE | Finance

Heading for Hong Kong

Chinese diabetes company Hua smooths path to Hong Kong IPO with venture rounds

March 30, 2018 12:20 AM UTC

Raising substantially more than planned in a pair of oversubscribed venture rounds gives Hua Medicine Ltd. more breathing room as the Shanghai diabetes company readies itself to be among the first biotechs to list in Hong Kong following the exchange’s rules revamp.

After raising $117.4 million from its series D and E rounds on March 27, the company should be able to complete Phase III trials of dorzagliatin and launch the Type II diabetes therapy in China...